News
Thermogenesis Holdings to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
The Process of Bringing a Clinical Discovery to Market – From Concept to Commercial for Cell and Gene Therapy Products
ThermoGenesis Holdings Announces Financial Results for the Second Quarter Ended June 30, 2021, and Provides Corporate Update
CDMO: An Approach for Scalability and Manufacturing
ThermoGenesis Holdings to Announce Financial Results for the Second Quarter Ended June 30, 2021 and Provide a Corporate Strategic Update
Transient Warming Events and the Effects on Cell Viability
Red Blood Cells and the Effects of Cell Processing
Cell Enrichment Methodologies Using Cord Blood as a Source: Automated vs Manual
Cell Storage Solutions for Cellular Manufacturing of Clinical Products
Cell Processing Technologies That Revolutionized the Cell and Gene Therapy Industry
Four Tips to Consider for Cryopreservation of Cell Therapies
The Importance of Automated Cell Washing for Cell Manufacturing
ThermoGenesis Holdings Announces Financial Results for the First Quarter Ended March 31, 2021 and Provides Corporate Update
ThermoGenesis Holdings to Announce Financial Results for the First Quarter Ended March 31, 2021 and Provide a Corporate Strategic Update
35 Years of ThermoGenesis: A Timeline of Events)
Immunotherapies Used to Treat Cancer
The History of Cell and Gene Therapy
Experimental Cell Therapies for COVID-19
ThermoGenesis Holdings Announces 2020 Year End Financial Results and Provides Corporate Update
